Early versus Late Discontinuation of Maintenance Therapy in ... - MDPI
One critical finding was an increased risk of developing a second primary malignancy (SPM) while on long-term lenalidomide maintenance. Patient Considerations IFM_05-May 2022
Patients are encouraged to discuss the balance between disease control and the toxic long-term effects of maintenance drugs with their oncology team. Early versus Late Discontinuation of Maintenance Therapy in
Research published around May 2022 explored the impact of "early" vs. "late" discontinuation (stopping before or after 3 years), noting that early stopping is often forced by toxicity rather than choice. Research published around May 2022 explored the impact
Lenalidomide was the primary drug used for maintenance in this study. Key Findings:
A significant number of patients (roughly 27%) had to stop the maintenance therapy early due to adverse side effects.
To determine if continuous low-dose chemotherapy after a transplant could improve overall survival and keep the disease controlled for longer periods.